Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Parameters of ligand binding, stimulation of low-Km GTPase, and inhibition of adenylate cyclase were determined in intact human
neuroblastoma
SH-SY5Y cells and in their isolated membranes, both suspended in identical physiological buffer medium. In cells, the mu-selective opioid agonist [3H]Tyr-D-Ala-Gly(Me)
Phe
-Gly-ol ([3H]DAMGO) bound to two populations of sites with KD values of 3.9 and 160 nM, with less than 10% of the sites in the high-affinity state. Both sites were also detected at 4 degrees C and were displaced by various opioids, including quaternary naltrexone. The opioid antagonist [3H]naltrexone bound to a single population of sites, and in cells treated with pertussis toxin the biphasic displacement of [3H]naltrexone by DAMGO became monophasic with only low-affinity binding present. The toxin specifically reduced high-affinity agonist binding but had no effect on the binding of [3H]naltrexone. In isolated membranes, both agonist and antagonist bound to a single population of receptor sites with affinities similar to that of the high-affinity binding component in cells. Addition of GTP to membranes reduced the Bmax for [3H]DAMGO by 87% and induced a linear ligand binding component; a low-affinity binding site, however, could not be saturated. Compared with results obtained with membranes suspended in Tris buffer, agonist binding, including both receptor density and affinity, in the physiological medium was attenuated. The results suggest that high-affinity opioid agonist binding represents the ligand-receptor-guanine nucleotide binding protein (G protein) complex present in cells at low density due to modulation by endogenous GTP.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Opioid signal transduction in intact and fragmented SH-SY5Y neural cells. 156 Feb 22
Previous studies have shown that serine protease inhibitors promote neurite outgrowth from
neuroblastoma
cells, sympathetic neurons and sensory ganglia in culture. In the present study, a neurite promoting activity of thrombin inhibitors such as hirudin, D-
Phe
,Pro,Arg-CH2Cl, and paraamidinophenylalanine derivatives, was found in rat embryo (E17) septal neurons in primary culture. In contrast, no effect was shown on choline acetyltransferase activity of septal fragments in culture. These results suggest that thrombin inhibitors might interact with a thrombin-like protease involved in the control of neurite outgrowth.
...
PMID:Enhancement of neurite outgrowth from central nervous system neurons in primary culture by thrombin inhibitors. 185 35
In order to determine affinities at the mu opioid receptor binding was conducted to intact SH-SY5Y
neuroblastoma
cells using the mu-selective ligand [3H][H-D-
Phe
-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] [( 3H]CTOP). Binding appeared to be a single receptor site, and a single state of the mu receptor. Under intact cell conditions, some but not all mu agonists display low affinity binding, while antagonists maintain high affinity for the mu receptor. These studies indicate the usefulness of [3H]CTOP for the determination of affinities at the mu receptor under physiological conditions.
...
PMID:Mu-opioid receptor binding in intact SH-SY5Y neuroblastoma cells. 196 47
Tetrahydrobiopterin (BH4) deficiency is a rare cause of hyperphenylalaninaemia (HPA) and usually leads to progressive neurological deterioration despite early dietary control of plasma
phenylalanine
concentrations. Dihydropteridine reductase (DHPR) deficiency is the most severe cause with respect to a fatal outcome. We report a 7-year-old girl with HPA diagnosed on neonatal Guthrie screening who at the age of 6 months had cytotoxic therapy for an adrenal
neuroblastoma
which secreted catecholamines. When 4 years old she was found to have DHPR deficiency. Although developmentally retarded and microcephalic she has failed to develop the florid neurological features often associated with the condition.
...
PMID:Neuroblastoma in a patient with dihydropteridine reductase deficiency. 220 64
Thyroid hormones must cross the plasma membrane to interact with nuclear or other intracellular receptors. In brain cells, most of the T3 in the nucleus is derived intracellularly from T4. While a saturable transport system has been demonstrated for T3 in a number of cell types, the evidence for such a system for T4 is less well established. In a mouse
neuroblastoma
cell line (NB41A3) the transport of T4 was found to be stereospecific, saturable, and energy dependent. When cells were incubated with radiolabeled hormone, the nuclear accumulation of L-T4 was 3.8-fold higher than that of D-T4, whereas isolated nuclei had a similar Ka for both enantiomers. Exposure of cells to antimycin and monodansylcadaverine decreased nuclear uptake of L-T4 (Ki of 197 and 55 microM, respectively), but had little effect on D-T4 uptake. Furthermore, L-system neutral amino acids, in particular L-
phenylalanine
at physiological concentrations, were shown to be competitive inhibitors of both T3 and T4 transport. In the presence of 0.1 mM L-
phenylalanine
the Km of the saturable plasma membrane transport of L-T3 increased 2.3-fold, and that of L-T4 increased 2.1-fold. In contrast, 1.0 mM L-serine or D-
phenylalanine
had little effect on L-T4 transport. This interaction of L-system amino acid and thyroid hormone transport may be of physiological importance.
...
PMID:The transport of thyroxine into mouse neuroblastoma cells, NB41A3: the effect of L-system amino acids. 235 Nov 15
Radioligand binding and functional assays were employed to demonstrate the existence of somatostatin receptors in the murine
neuroblastoma
clone N1E-115. Saturation experiments with [125I][Tyr11]somatostatin-14 indicated the presence of a single class of binding sites in membranes prepared from N1E-115 cells (Kd = 83 pM; Bmax = 21,000 receptors/cell). Somatostatin-14, somatostatin-28 and L363586 (cyclo(N-Me-ALA-TYR-D-TRP-LYS-VAL-
PHE
] all displaced the 125I-ligand monophasically in N1E-115 cells (Ki values were 28, 82 and 34 pM, respectively), which contrasted with the binding heterogeneity apparent with L363586 in rat brain membranes. The binding of [125I][Tyr11]somatostatin-14 was reduced by GppNHp, indicating that N1E-115 somatostatin receptors interacted with guanine nucleotide binding protein(s). Somatostatin agonists decreased by 30-50% the levels of [3H]cyclic AMP induced in intact cells by forskolin, prostaglandin E1, or vasoactive intestinal polypeptide. The EC50 values for inhibition of the [3H]cyclic AMP response to PGE1 by L363586, somatostatin-14, and somatostatin-28 were 0.24, 0.63 and 1.0 nM, respectively. Pertussis toxin treatment of N1E-115 cells reduced both binding to the receptor and the functional response to somatostatin-14. These data suggest that a single class of somatostatin receptors in N1E-115 cells are linked to the inhibition of adenylate cyclase through a Gi protein.
...
PMID:Biochemical evidence for somatostatin receptors in murine neuroblastoma clone N1E-115. 256 62
Tritiated DTLET (Tyr-D-Thr-Gly-
Phe
-Leu-Thr) binds with high affinity, specificity and saturability to
neuroblastoma
N18TG2 and hybrid
neuroblastoma
x glioma NG108-15 and NG108-5 intact cells. The delta-opioid receptor density in cells cultured in chemically defined medium was increased about 2 times compared to that in cells cultured in 10% fetal calf serum. A major and a minor protein species covalently and specifically bound to [125I]azido-DTLET (Tyr-D-Thr-Gly-pN3Phe-Leu-Thr), photoactivatable ligand, migrated on SDS-gel electrophoresis with Mr values near 33,000 and 58,000, respectively.
...
PMID:Photoaffinity labeling of a 33 kDa protein subunit of the delta-opioid receptor in neuroblastoma and hybrid cell lines. 283 23
Two series of dimeric enkephalin analogues were assayed for opioid activity in two isolated smooth muscle preparations: the guinea pig ileum (GPI) and the mouse vas deferens (MVD). Dimers have the general structure: X-(CH2)n-X, where X is H-Tyr-D-Ala-Gly-
Phe
-Leu-NH-(n = 0, 2, 4, 6, 8, 10, 12), for the first series of dimeric pentapeptide enkephalins (DPEn), and H-Tyr-D-Ala-Gly-
Phe
-NH-(n = 2, 4, 6, 8, 12), for the series of dimeric tetrapeptide enkephalins (DTEn). Comparison of biological activities with binding affinities revealed that: (1) the DPE series with n = 2-8 showed increased potency in the MVD assay relative to monomeric [D-Ala2, Leu5]enkephalinamide (DALEA); (2) there was an associated increase affinity for the delta receptor of rat brain or
neuroblastoma
-glioma hybrid cells. (however, the relative potencies were higher in the MVD assay then predicted on the basis of binding affinities); (3) the DTE series also showed an increase in delta receptor affinities and MVD potencies relative to DALEA, for n = 2-12; (4) for the DTE series, the increase in MVD activities was less than that expected on the basis of delta binding affinity; (5) for both the DPE and DTE series, activities in the GPI assay and mu-receptor affinities were highly correlated: as the length of the methylene bridge increased from 2 to 12, there was a progressive loss of activity in both assays, with a similar pattern for DPE and DTE. Two selected dimers and their corresponding monomers were also assayed for antinociceptive activity in vivo: results were consistent with GPI and mu-binding but not with MVD and delta-binding. Two alkylamide analogs of penta- and tetrapeptide monomers, representing the monomer with the attached spacer of the most active dimers, were also assayed in biological and binding assays. Comparison of these compounds with the corresponding dimers suggest that the changes in activities and selectivities induced by dimerization are not a spurious effect of the presence of an akylamide derivative of the carboxy terminal of enkephalin but rather may represent a specific effect due to the bivalent nature of the ligands.
...
PMID:Receptor binding and biological activity of bivalent enkephalins. 298 28
The binding of alkylendiamide dimers of the three N-terminal residues of [D-Ala2,D-Leu5]enkephalin (DADL) to rat brain and Ng108-15
neuroblastoma
-glioma cell membranes was compared with that of DADL, Tyr-D-Ala-Gly-NMe-
Phe
-Gly-ol (DAGO) and morphiceptin. Tritiated DADL and DAGO were used as labeled ligands for delta- and mu-receptors, respectively. Dimerization of the tripeptides resulted in dramatic increases in both mu and delta binding. The binding to mu-receptors showed two peaks at an alkyl chain length of n = 2 and approximately n = 16. In contrast, delta binding (NG108-15 cells) increased steadily with increasing chain length. The dimers with n less than 18 were mu-preferential, and the one with n = 2 showed the most dramatic increase in mu selectivity with a 400 fold higher affinity to mu- than to delta-receptors. For long-chain alkyl spacers the compounds became delta selective.
...
PMID:Increased affinity and selectivity of enkephalin tripeptide (Tyr-D-Ala-Gly) dimers. 299 Sep 53
The human
neuroblastoma
cell line designated NMB (Brodeur et al., 1977, Cancer 40: 2256) has been shown to have specific opiate binding sites. These sites are highly stereospecific. Two characteristic delta specific peptides, D-Ala2-D-Leu5 enkephalin and D-Thr2-D-Thr6 enkephalin, have high affinity for the binding sites. Morphine binds specifically but with a much lower affinity. Dextrorphan and the mu specific peptide morphiceptin (Tyr-Pro-
Phe
-Pro-CO-NH2) do not bind to the site. The binding sites are heat and trypsin sensitive. Sodium ions specifically lower agonist binding to the sites. Approximately 14,000 binding sites per cell are found. The binding characteristics of these sites are very similar to those of the delta sites characterized on mouse
neuroblastoma
cell lines.
...
PMID:NMB: a human neuroblastoma cell line with specific opiate binding sites. 300 Mar 78
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>